PTCT•benzinga•
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
Summary
PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available in Europe.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 20, 2024 by benzinga